Education
About Us
Working with TipRanks
Follow Us
Novartis Ag (DE:NOTA)
FRANKFURT:NOTA
NOTA Stock Chart & Stats
€132.50
€3.60(3.86%)
At close: 4:00 PM EST
€132.50
€3.60(3.86%)
Day’s Range― - ―
52-Week Range€88.20 - €132.50
Previous CloseN/A
Volume500.00
Average Volume (3M)35.00
Market Cap
€250.04B
Enterprise Value€324.94B
Total Cash (Recent Filing)€11.59B
Total Debt (Recent Filing)€37.11B
Price to Earnings (P/E)20.2
Beta0.61
Next Earnings
Apr 28, 2026EPS Estimate
1.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.70
Shares Outstanding2,112,421,900
10 Day Avg. Volume61
30 Day Avg. Volume35
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)5.79
Price to Sales (P/S)4.88
P/FCF Ratio15.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€104.58Price Target Upside-21.07% Downside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceIncreased cash on the balance sheet has led to a modestly higher target price for Novartis.
Product ApprovalCosentyx is maintaining its NBRx share despite increased competition and is expected to grow further with the approval of the HS indication and IV formulation.
Trial ResultsKisqali's NATALEE trial results have received positive feedback from physicians, indicating excitement for its use among eBC patients.
Bears Say
Revenue ExpectationsThe target price implies modest upside from current levels, suggesting that revenue upside is mostly priced in.
Novartis News
NOTA FAQ
What was Novartis Ag’s price range in the past 12 months?
Novartis Ag lowest stock price was €88.20 and its highest was €132.50 in the past 12 months.
What is Novartis Ag’s market cap?
Novartis Ag’s market cap is €250.04B.
When is Novartis Ag’s upcoming earnings report date?
Novartis Ag’s upcoming earnings report date is Apr 28, 2026 which is in 76 days.
How were Novartis Ag’s earnings last quarter?
Novartis Ag released its earnings results on Feb 04, 2026. The company reported €1.705 earnings per share for the quarter, beating the consensus estimate of €1.665 by €0.039.
Is Novartis Ag overvalued?
According to Wall Street analysts Novartis Ag’s price is currently Overvalued.
Does Novartis Ag pay dividends?
Novartis Ag does not currently pay dividends.
What is Novartis Ag’s EPS estimate?
Novartis Ag’s EPS estimate is 1.8.
How many shares outstanding does Novartis Ag have?
Novartis Ag has 2,112,421,900 shares outstanding.
What happened to Novartis Ag’s price movement after its last earnings report?
Novartis Ag reported an EPS of €1.705 in its last earnings report, beating expectations of €1.665. Following the earnings report the stock price went up 2.789%.
Which hedge fund is a major shareholder of Novartis Ag?
Currently, no hedge funds are holding shares in DE:NOTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novartis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€104.58 (-21.07% Downside)
€104.58 (-21.07% Downside)
Blogger Sentiment
Bullish
DE:NOTA Sentiment 91%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 82%
Bearish news 18%
Bearish news 18%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.28%
12-Months-Change
Fundamentals
Return on Equity
31.14%
Trailing 12-Months
Asset Growth
8.25%
Trailing 12-Months
Company Description
Novartis Ag
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
NOTA Company Deck
NOTA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong multi-product commercial momentum, record profitability and cash generation, and a robust late-stage pipeline with multiple potential catalysts in 2026. Management acknowledged notable near-term headwinds — chiefly mid-2025 generic entries (Entresto, Promacta, Tasigna), noisy Q4 gross-to-net adjustments, the largest GX impact expected in 2026, and some clinical/regulatory timing uncertainties (pelacarsen event rates, remibrutinib monitoring, zigakibart timing). However, the breadth of blockbuster growth across key brands, record margins and cash flow, clear capital allocation, and a defined plan to return to 40%+ core margins by 2029 outweigh the near-term challenges.View all DE:NOTA earnings summariesNOTA Stock 12 Month Forecast
Average Price Target
€104.58
▼(-21.07% Downside)
Technical Analysis
Options Prices
Currently, No data available
---